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Background/introduction
We have recently conducted a clinical phase I study to
assess the safety and spatial accuracy and precision of a
newly developed dedicated MR-HIFU system for lateral
breast tumor ablation [1]. Here, we report on patient
inclusion, treatment efficacy and safety.
Methods
All treatments were performed on a dedicated breast
MR-HIFU system (Philips Healthcare, Vantaa, Finland)
integrated with a clinical 1.5-T MRI scanner (Achieva,
Philips Healthcare, Best, The Netherlands). Ten female
patients with i) pathologically proven invasive breast
cancer after large-core needle biopsy and ii) tumor size
≥ 1 cm were included. The patients were under proce-
dural sedation during the complete HIFU procedure.
Fat-suppressed segmented Echo Planar Imaging was
performed for PRFS-based thermometry. Online correc-
tion of the respiration-induced field disturbances was
performed by a Look-Up Table (LUT)-based method
[2]. Partial tumor ablation was performed to allow for
histological analysis of viable versus ablated tumor tis-
sue. The number of sonication performed per patient
(1-5) and the acoustic power (50-90 W) used for each
sonication was variable. Surgery was performed at least
48 h after the MR-HIFU procedure. After surgical resec-
tion H&E and cytokeratin 8/18 staining was performed
on histological sections. In order to assess the safety of
the system i) the skin of the treated breast was carefully
evaluated by a physician, ii) patients were asked to
report pain scores according to the Numerical Rating
Scale, with a score of 0 (no pain) to 10 (worst pain ima-
ginable) and iii) the temperature evolution in the tem-
perature imaging slice positioned on the pectoral muscle
was analyzed to evaluate possible unintended heating in
the far field during tumor ablation.
Results and conclusions
Seventeen patients were initially enrolled in the study.
Seven patients were excluded or withdrew from the
study after a pre-treatment MRI scan.
Finally, 10 patients (8 patients with invasive ductal carci-
noma and 2 patients with invasive lobular carcinoma)
underwent MR-HIFU ablation. The procedural sedation
protocol was improved in the course of the clinical study.
This lead to less sonication related motion and involuntary
patient motion. In addition, the respiration became more
regular and shallower, which improved the quality of MR
thermometry. The maximum temperature in the focal
point increased with increasing power in each patient.
Sonications performed with the same acoustic power in
different patients lead to different maximum temperatures
in the focal point. Finally, clear thermal damage was
observed in the tumor tissue in 5 patients.
The absence of thermal damage in the other patients was
due to technical problems that prevented the sonication to
reach temperatures inside the tumor leading to tissue
damage. In none of the patients, skin redness, skin burns
or other signs of skin damage were observed. Nausea and
vomiting in the hours after the MR-HIFU procedure were
reported as minor adverse events in one patient. Only
two patients reported pain (maximum score of 5) after the
MR-HIFU treatment. No temperature increases related to
the tumor ablation were observed in the pectoral muscle
during sonication. In conclusion, breast tumor ablation
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with the dedicated breast MR-HIFU system is safe and
technical feasible. A good sedation protocol during HIFU
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